Related Experiment Video
Updated: Jul 21, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.0K
Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and
Mingxia Zhu1, Xiaping Wang2, Qing Zhang3
1Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Aging
|February 5, 2024
Summary
Targeting Protein for Xenopus Kinesin Like Protein 2 (TPX2) is overexpressed in many cancers and linked to poor prognosis. TPX2 impacts tumor microenvironment and predicts response to cancer therapies, suggesting its potential as a biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Targeting Protein for Xenopus Kinesin Like Protein 2 (TPX2) is a microtubule-associated protein crucial for spindle assembly and implicated in tumorigenesis.
- Understanding the pan-cancer role of TPX2 is essential for developing novel diagnostic and therapeutic strategies.
Purpose of the Study:
- To investigate the prognostic and immunological significance of TPX2 across various solid tumors.
- To evaluate TPX2 as a potential diagnostic, prognostic, and immunotherapy biomarker in pan-cancer analysis.
Main Methods:
- Utilized TCGA, TISCH, and HPA databases for expression pattern, diagnostic, and prognostic value assessment.
- Assessed genomic alterations using cBioPortal and performed in vitro experiments in lung adenocarcinoma (LUAD).
- Conducted single-cell analysis, tumor microenvironment correlation, and drug sensitivity analysis.
Main Results:
- TPX2 was overexpressed in 22 cancer types, positively correlated with CNV and negatively with methylation, predicting worse outcomes.
- TPX2 was predominantly found in malignant cells and proliferating T cells; its expression correlated with tumor microenvironment and immune genes.
- TPX2 expression predicted responses to chemotherapy and immunotherapy; knockdown in LUAD cells reduced proliferation and migration.
Conclusions:
- TPX2 serves as a significant diagnostic and prognostic biomarker in a wide range of cancers.
- TPX2's association with the tumor immune microenvironment and its predictive value for therapy response highlight its potential as an immunotherapy marker.
More Related Videos
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.